CTLA4 and neoplasm: The striking success of immune checkpoint inhibitors targeting PD-1, PD-L1, CTLA-4 and other modulators of the immune reaction in various tumor entities such as melanoma, non-small-cell lung cancer, kidney cancer and bladder cancer have raised the interest in the composition and activity of the tumor infiltrating lymphocytes such as the proliferating subset of cytotoxic T-cells [8, 9].